** Shares of PTC Therapeutics PTCT.O rise 4.6% to $55.17 in morning trade
** Brokerage J.P.Morgan raises PT to $78 from $72, representing a 47.8% upside to the stock's last close
** "We continue to see PTCT shares as under-appreciated by the Street ahead of two compelling launches in established markets" - J.P. Morgan says
** PTC expects regulatory decisions on co's drugs - sepiapterin to treat the genetic condition phenylketonuria (PKU), and vatiquinone to treat nervous system disorder Friedreich ataxia - this year
** Brokerage says current peak sales estimate of ~$700 mln by 2031 for sepiapterin is "overly conservative"
** Nine of 15 brokerages rate the stock "buy" or higher, four "hold", two "sell" or lower; their median PT is $63.92, according to data compiled by LSEG
** Up to last close, PTCT has risen 71.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.